Gilead to sign $275M deal with cancer drugmaker

Gilead announced June 23 it will buy 49.9 percent of San Francisco-based immunotherapy company Pionyr for $275 million, with the option to buy out the company entirely.

The deal will allow Gilead to take on Pionyr's technology, namely its myeloid-tuning therapy, which rebalances a tumor's microenvironment to privilege immune-activating cells over immune-suppressing ones. Gilead is focusing on PY314 and PY159, Pionyr's two preclinical antibodies developed to enhance anti-tumor immunity.

The myeloid-tuning technology exhibits potential to treat patients who are resistant to checkpoint inhibitor therapies.

"The agreement represents important progress as we continue to build out Gilead's presence in immuno-oncology with innovative and complementary approaches," Daniel O'Day, Gilead's CEO, said in a news release.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like

Featured Whitepapers

Featured Webinars